RevolKa Ltd., a biotech innovator specializing in AI powered protein engineering, announced it has secured $1.4 million in a Series A extension funding round.
This capital injection will support the company’s efforts to speed up drug discovery programs targeting rare diseases and expand key industry partnerships.
Strong Backing from Strategic Investors
The funding was co-led by RevolKa’s existing investors, D3 LLC and TOHOKU University Venture Partners, with additional support from DEEPCORE Inc., a Tokyo based VC firm focused on AI startups. This investment underscores confidence in RevolKa’s cutting-edge technology and growth potential.
Innovating Drug Development with AI Protein Design
RevolKa’s proprietary platform, aiProtein®, combines artificial intelligence and protein engineering to design novel proteins tailored to treat rare and hard-to-treat diseases.
By leveraging AI, the company aims to reduce development time and increase the success rate of drug candidates entering clinical trials.
Plans for Growth and Collaboration
The new funds will be used to enhance RevolKa’s research capabilities, improve the aiProtein® platform, and accelerate preclinical studies of promising drug candidates.
Several candidates have already demonstrated positive lab results, paving the way for future clinical development.
RevolKa also plans to deepen collaborations with academic institutions and pharmaceutical companies to broaden applications of its AI driven protein engineering across multiple therapeutic areas.
About RevolKa Ltd.
Founded in 2021 and based in Sendai, Japan, RevolKa is dedicated to transforming drug discovery by merging AI and protein engineering.
Their mission is to develop innovative protein-based therapies that address unmet medical needs and improve patient outcomes worldwide.
